ACTRIMS 2024: Tolebrutinib fails to eliminate iron rim lesions in Phase 2 trial
Nearly one year of treatment with tolebrutinib, an oral small molecule being developed by Sanofi, failed to eliminate iron rim lesions in adults with multiple sclerosis (MS), according to data from a small Phase 2 clinical trial. Researchers are continuing to examine study results to determine…